Page 158 - 2022_03-Haematologica-web

A.N. Bastidas Torres et al.
bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc Natl Acad Sci U S A. 1999;96(13):7172-7177.
43. Ali S, Nouhi Z, Chughtai N, Ali S. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J Biol Chem. 2003;278(52):52021-52031.
44. Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature. 2001;409(6818):349-354.
45.Wu L, Bijian K, Shen SH. CD45 recruits adapter protein DOK-1 and negatively reg- ulates JAK-STAT signaling in hematopoiet- ic cells. Mol Immunol. 2009;46(11- 12):2167-2177.
46. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11): 798-809.
47. Kleppe M, Koche R, Zou L, et al. Dual tar- geting of oncogenic activation and inflam- matory signaling increases therapeutic effi-
cacy in myeloproliferative neoplasms.
Cancer Cell. 2018;33(1):29-43.
48. Zinzani PL, Musuraca G, Tani M, et al.
Phase II trial of proteasome inhibitor borte- zomib in patients with relapsed or refracto- ry cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293-4297.
49. Nicolay JP, Muller-Decker K, Schroeder A, et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF- kappaB. Blood. 2016;128(6):805-815.
714
haematologica | 2022; 107(3)